Press Release FeedGet the RSS feed
Menu

Business Wire

NFL Biosciences Receives Regulatory Approval to Begin Its Phase 2 TONIC Trial for Smoking and Nicotine Cessation

Business Wire

  • The TONIC Phase 2 trial evaluating NFL-102 consists of Part A (the first 40 participants) and Part B (the next 270 participants)

  • Enrollment of the first participants (Part A) is scheduled to begin in November 2026

  • Analysis and communication of the results from Part A expected in April 2027

MONTPELLIER, France, October 22, 2026--Regulatory News:

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing immunotherapies for smoking and nicotine cessation, announced today that it has obtained the necessary approvals from the French National Agency for Medicines and Health Products Safety (ANSM) and the Committee for the Protection of Human Subjects (CPP) to begin its Phase 2 TONIC study evaluating NFL-102 for smoking and nicotine cessation.

NFL-101 AND NFL-102: TWO DISTINCT IMMUNOTHERAPIES

NFL-101 is designed to reduce neuroinflammation and has demonstrated statistically significant efficacy in a Phase 2 trial in a population defined by an immune biomarker predictive of response, identified in post-hoc analyses. A manuscript presenting these results is currently being submitted to an international peer-reviewed scientific journal. NFL-102, on the other hand, targets a root cause of addiction: alterations in brain plasticity. The TONIC study will now evaluate its efficacy in smoking and nicotine cessation.

TONIC STUDY

The TONIC study plans to enroll 310 smokers in France in a multicenter, randomized, double-blind, placebo-controlled trial. Its adaptive design will allow for the gradual selection of one dose from among three initial doses. The primary endpoint will be continuous abstinence for four weeks, confirmed by urinary cotinine.

Part A

An initial analysis will focus on the first 40 participants, included in the Eurofins Optimed Clinical Center (Gières, 38), and one dose will be eliminated based on safety and efficacy data analyzed—after unblinding—by an Independent Data Monitoring Committee (IDMC) and the company.

The first enrollments are scheduled for November 2026, and the analysis of the results from Part A is scheduled for April 2027. These two milestones will be the subject of dedicated announcements.

Part B

After enrolling an additional 150 participants (50 per arm, randomized between the two selected dose arms and the placebo) at about ten clinical centers in France, an interim analysis conducted by the IDMC will identify the most effective dose, without unblinding the other parties involved in the study. The study will then continue exclusively with this selected dose compared to placebo, with the enrollment of an additional 120 participants (60 per arm, randomized between the selected dose and placebo).

  1. CybersecurityTeam CymruTeam Cymru Supports INTERPOL's Operation Serengeti III, Disrupting Cybercriminal Networks Across AfricaGlobal operation results in 1,462 arrests, disruption of nearly 11,000 malicious networks and recovery of more than $105 million in illicit funds LAKE MARY, Fla., October 22, 2026--Team Cymru today announced its participation as a private-sector partner in INTERPOL's Operation Serengeti III, a coordina
  2. BankingCTBC Bank Honored for the Fifth Time by The CorporateTreasurer, Winning Three Major Awards and Reinforcing Its Regional LeadershipTAIPEI, Taiwan, October 22, 2026--Demonstrating excellence in institutional banking and cross-border financial solutions, CTBC Bank has once again been honored by the international financial publication The CorporateTreasurer , marking its fifth accolade from the publication. The bank won three major h
  3. Pernod Ricard Successfully Completes Hybrid Bonds Issuance of €1.5 BillionPARIS, October 22, 2026--Regulatory News: Press Release – Paris, 22nd October 2026 Not for distribution directly or indirectly in Canada or Japan. The distribution of this document in certain jurisdictions may be restricted by law. Persons who come into possession of this document are required to inqui
  4. E3 LITHIUM LTD.E3 Lithium Approaches Completion of Phase 2 of its Demonstration Facility and Outlines Path to CommercializationDemonstration Facility, permitting, offtake, and strategic partnerships progressing in parallel CALGARY, Alberta, October 22, 2026--E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), "E3", "E3 Lithium", or the "Company" is approaching completion of Phase 2 of its Demonstration Facility and provides
  5. AutomotiveEOS Defence SystemsEOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech ProgrammesVOP CZ's TAROS is an autonomous and remote-controlled robotic ground vehicle designed for military logistics and support missions The Bushmaster Protected Mobility Vehicle (PMV) is a 4x4 armored infantry mobility vehicle designed by Thales Defence Australia, with licenced production to VOP CZ PRAGUE, October 22, 2026 --(
  6. AIBlack HatBlack Hat Europe Returns to the Excel London with Briefings, Summits, and Trainings Confronting Today's Most Urgent Cyber ThreatsKey themes driving this year's lineup are AI & Autonomous Threats; Cyber Conflict & Live Operations; Systems Under Stress; and Identity, Trust, & Control LONDON, October 22, 2026--Black Hat , the cybersecurity industry's most established and in-depth security event series, today announced the release